

No. 31026/176/2021-MD (Part-3)
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals

Shastri Bhawan, New Delhi – 110 001
Dated 9th January 2026

Public Notice No. 1/2026

Subject: Exemption from Global Tender Enquiry under rule 161(iv) of the General Financial Rules, 2017

In addition to 84 formulations published vide this Department's Public Notice No. 1/2025 dated 21.11.2025(copy enclosed), this Department has received additional requests from the pharmaceutical industry seeking inclusion of certain patented/non-patented/ proprietary formulations under the Global Tender Enquiry (GTE) exemption list, on the ground of non-availability of domestic manufacturing.

2. A list of the formulations to which these requests relate is at Annex A.
3. Local manufacturers are hereby invited to submit objections (based on domestic manufacturing availability) against inclusion of any formulations listed at Annex A in the GTE exemption list, in the form set out at Annex B, by 19.01.2026 through email sent to so-pharmapolicy@pharma-dept.gov.in
4. This issues with the approval of competent authority.



(Dharmendra Kumar Yadav)
Under Secretary to the Government of India
Tel.: 011 23071162

Annex A

Additional formulations under consideration for inclusion in Global Tender Enquiry (GTE) exemption list in FY 2025-26.

S. No.	Pharmaceutical formulation and strength	Status- Patented or Proprietary (based on submission from industry)
1.	Donanemab 350 mg/20 ml (17.5 mg/ml) solution for IV infusion in a single-dose vial (r-dna origin)	Patented
2.	Marstacimab 150mg/ml	Patented
3.	Elranatamab 44mg/1.1 ml (40mg/ml) and 76mg/1.9ml (40mg/ml) (r-dna origin)	Patented
4.	Inj. tildrakizumab 100 mg/ml	Patented
5.	Remifentanil hydrochloride 1mg & 2mg vial	Not patented
6.	Tocilizumab injection 162mg/0.9ml (in Pre-filled Syringe For Subcutaneous Use)	Proprietary
7.	Insulin Lispro I.P. (r-DNA origin) in pre-filled pen 100IU/ml, 3ml solution for injection	Proprietary
8.	Insulin lispro I.P. (r- DNA origin), 100 IU/ml prefilled pen.	Proprietary
9.	Insulin lispro i.p. (r- DNA origin), solution for injection in pre-filled pen 200 u/ml.	Proprietary
10.	Insulin Lispro Ultrarapid (UR) injection 100 units/ml, solution for injection as 3ml prefilled pen	Proprietary
11.	Insulin Lispro Ultrarapid (UR) Injection 100 units/ml, solution for injection as 3ml cartridge.	Proprietary

To:

Department of Pharmaceuticals
Ministry of Chemicals and Fertilizers
Government of India
Shastri Bhawan, New Delhi – 110 001

Subject: Exemption from Global Tender Enquiry under rule 161(iv) of the General Financial Rules, 2017 — Objections against inclusion of formulations listed at Annex A to Public Notice No. 1/2026 — regarding

Reference is invited to the Public Notice No. 1/2026 issued by the addressee Department inviting objections from local manufacturers (based on domestic manufacturing availability) against inclusion of formulations listed at Annex A to the said notice under the Global Tender Enquiry (GTE) exemption list.

2. In this connection, I give below the details of information regarding the formulation objected against for inclusion in the GTE exemption list on account of its domestic manufacturing availability with necessary particulars are furnished as under:

S. no	Details	Information
1	Name and serial number of formulation from Annex-A against which objection is raised	
2	Name of the local manufacturing entity	
3	Address of the registered office and manufacturing location (complete postal address)	
4	Contact details, email id and phone numbers (mobile and office)	
5	Generic name of locally manufactured drug and its strength	
6	Brand name of drug mentioned against S. no. 5	
7	Local content percentage of the drug as per the DPIIT OM dated 19.7.2024	
8	Manufacturing capacity per annum	
9	Manufacturing license (mandatory)	
10	Patent certificate, if any.	

3. The aforesaid information is true and correct to the best of my knowledge and nothing material has been concealed therefrom.

Yours faithfully

Place: _____

Date: _____

(Signature of the authorised signatory)

Name: _____

Designation: _____